Medicare panel backs $93K cancer drug Provenge
Medicare advisers on Wednesday supported the effectiveness of the prostate cancer drug Provenge, an innovative therapy that has prompted questions about the cost of medical care and the government's role in paying for it.
The vote by a 14-member panel of outside experts amounts to a recommendation that Medicare pay for Provenge, which costs $93,000 per patient and extends life an average of four months.
- In Lakeport, CA, a Population Health Laboratory is Born
- Nurse Ethics Comes to a Head at Guantanamo Bay
- Transforming Decision Support and Reporting
- Providers' Push to Consolidate Roils Payers
- CMS Mulls Income-Adjusting MA Stars
- As Retail Clinics Surge, Quality Metrics MIA
- Providers Prep for New Payment Models as Population Health Grows
- Insurers' listings of in-network doctors often out of date
- How to navigate big data in healthcare
- Slideshow: Healthcare Executives Eye Efficiency